This is the text extract for June Tender Notification., browse documents here.

---

30 June 2010

TENDER RESULTS

The PHARMAC Board (or Chief Executive under delegated authority) has resolved to accept and decline tenders for Sole Subsidised Supply and Hospital Supply Status for some of the products included in the Invitation to Tender dated 21 December 2007, the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009. Some of the pharmaceuticals that will be delisted when the period of sole supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts until such time as the pharmaceuticals are delisted and PHARMAC will continue to subsidise their pharmaceuticals accordingly. Product Notification Forms Please note that for all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) suppliers are required to notify PHARMAC and the Guild by 4pm 12th July 2010. More information and product notification forms can be downloaded from our website – www.pharmac.govt.nz/schedule.asp. 2007/08 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 1. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on 1 August 2010 and Sole Supply Status commences 1 November 2010.

The decisions were as follows:

Chemical Name Calcium carbonate Calcium carbonate

Presentation; Pack size and type Tab 1.25 g (500 mg elemental); 250 tablets, bottle Tab 1.5 g (600 mg elemental); 250 tablets, bottle

Current Subsidy and price $9.18 $10.33

New tender subsidy $9.08 $10.18

Sole supply brand (Supplier) Calci-Tab 500 (AFT) Calci-Tab 600 (AFT)

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 21 December 2007.

The decisions were as follows:

Chemical Name Ethinyloestradiol with Levonorgestrel Ethinyloestradiol with Levonorgestrel Fluconazole Intra-Uterine Device Isosorbide Mononitrate Isosorbide Mononitrate

Line Item Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets Oral liq 10 mg per ml IUD Tab 20 mg Tab long-acting 40 mg

A351384 - qA15909

---

2008/09 Tender Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender, dated 23 December 2008.

The decisions were as follows:

Chemical Name Losartan Losartan Losartan Losartan Losartan Noradrenaline Acid Tartrate Sodium Bicarbonate Sodium Bicarbonate Stavudine

Line Item Tab 25 mg Tab 50 mg Tab 100 mg Tab 50 mg with hydrochlorothiazide 12.5 mg Tab 100 mg with hydrochlorothiazide 25 mg Inj 1 mg per ml, 2 ml Inj 8.4%, 50 ml Inj 8.4%, 100 ml Cap 40 mg

2009/10 Tender Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule 2. Tenders awarded to listed pharmaceuticals where no other brand is listed – subsidy changes (where applicable) on 1 August 2010 and Sole Supply Status commences 1 November 2010.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type

Current Subsidy and price $46.33 ($47.72) $6.30 $2.10

New tender subsidy $60.00 $5.36 $1.85

Sole supply brand (Supplier) Imuran (Aspen) Inhibace Plus (Roche) Methatabs (API Consumer)

Azathioprine Cilazapril with hydrochlorothiazide Methadone hydrochloride

Inj 50 mg; 1 injection, vial Tab 5 mg with hydrochlorothiazide 12.5 mg; 28 tablets, blister Tab 5 mg; 10 tablets, blister

3. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brands at the tender subsidy will occur on 1 August 2010, reference pricing of nontender winning brands will occur on 1 October 2010 and Sole Subsidised Supply commences on 1 January 2011.

The decisions were as follows:

Chemical Name

Presentation; Pack size and type Tab 100 mg; 500 tablets, bottle Tab 50 mg; 100 tablets, blister Inj 1 g; 5 injections, vial Nebuliser soln, 250 µg per ml, 1 ml; 20 nebuliser solutions, ampoule

Current Subsidy and price $17.25 $26.75*

New tender subsidy $13.80 $18.45

Sole supply brand (Supplier) Vitala-C (Boucher and Muir) Imuprine (Mylan)

Brands affected by reference pricing and delisting Apo-Ascorbic Acid (Apotex) Azamun (Douglas) Imuran (Aspen) AFT (AFT) Ipratropium Steri-Neb (Airflow)

Ascorbic acid Azathioprine Ceftriaxone sodium** Ipratropium bromide

$5.40 (per $10.49 (5 Aspen Ceftriaxone injection) injections) (Aspen) $4.30 $3.79 Univent (Rex Medical)

A351384 - qA15909

Page 2 of 4

---

Chemical Name

Presentation; Pack size and type Nebuliser soln, 250 µg per ml, 2 ml; 20 nebuliser solutions, ampoule Tab 2.5 mg; 90 tablets, blister Liq 0.5%; 200 ml OP, bottle

Current Subsidy and price $5.25 $4.00 (per 100 tablets) $4.99

New tender subsidy $4.06 $2.95 $3.79 $25.00 $1.50 $0.80

Sole supply brand (Supplier) Univent (Rex Medical) Dapa-Tabs (Mylan) A-Lices (AFT) Micolette (AFT) Accord (Arrow) Accord (Arrow)

Brands affected by reference pricing and delisting Ipratropium Steri-Neb (Airflow) Napamide (Douglas) Derbac-M (SSL New Zealand) Microlax (Johnson and Johnson) Apo-Terazosin (Apotex) Apo-Terazosin (Apotex) Apo-Terazosin (Apotex)

Ipratropium bromide Indapamide Malathion Sodium citrate with sodium lauryl sulphoacetate Terazosin hydrochloride Terazosin hydrochloride Terazosin hydrochloride

Enema 90 mg with sodium lauryl $7.30 (per sulphoacetate 9 mg per ml, 5 ml; 50 12 enemas) enemas, tube Tab 1 mg; 28 tablets, blister Tab 2 mg; 28 tablets, blister $2.50 $23.30 (per 500) $29.00 (per 500)

Tab 5 mg; 28 tablets, blister

$1.00

Accord (Arrow)

*There are two different subsidies. The subsidy of the fully funded product is indicated. **The tender decisions for ceftriaxone sodium 500 mg injection will be notified in the July tender notification.

4. Tenders awarded to an unlisted pharmaceutical – listing for tender winning brand at the tender subsidy will occur on 1 August 2010 and Sole Subsidised Supply commences on 1 November 2010.

The decision was as follows:

Chemical Name Tamsulosin hydrochloride

Presentation; Pack size and type Cap 400 mg; 30 capsules, blister

New tender subsidy $5.98

Sole supply brand (Supplier) Tamsulosin-Rex (Rex Medical)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule 5. Tender awarded to a listed pharmaceutical where only the current brand is listed – price change for hospital tender winning brand of the pharmaceutical will occur in Part II of Section H of the Pharmaceutical Schedule on 1 August 2010; the DV Limit will apply from 1 October 2010

The decisions were as follows:

Chemical Name Methadone hydrochloride

Presentation; Pack size and type Tab 5 mg; 10 tablets, blister

Hospital Supply Brand (Supplier) Methatabs (API Consumer)

Pack Price $1.85

DV Limit 1%

6. Tenders awarded to listed pharmaceuticals where an alternative brand is already listed – listing of the hospital tender winning brand of the pharmaceuticals will occur in Part II of Section H of the Pharmaceutical Schedule on 1 August 2010; DV Limits will apply from 1 October 2010; delisting of the other brands in Section H will occur on 1 October 2010.

The decisions were as follows:

Chemical Name Ceftriaxone sodium* Ipratropium bromide Ipratropium bromide Indapamide Sodium citrate with sodium lauryl sulphoacetate

Presentation; Pack size and type Inj 1 g; 5 injections, vial Nebuliser soln, 250 µg per ml, 1 ml; 20 nebuliser solutions, ampoule Nebuliser soln, 250 µg per ml, 2 ml; 20 nebuliser solutions, ampoule Tab 2.5 mg; 90 tablets, blister Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml; 50 enemas, tube

Hospital Supply Brand (Supplier) Aspen Ceftriaxone (Aspen) Univent (Rex Medical) Univent (Rex Medical) Dapa-Tabs (Mylan) Micolette (AFT)

Pack Price $10.49 $3.79 $4.06 $2.95 $25.00

DV Limit 1% 1% 1% 1% 1%

A351384 - qA15909

Page 3 of 4

---

*Tender decisions for ceftriaxone sodium 500 mg injection and 2 g infusion will be notified in the July tender notification.

7. Tenders awarded to pharmaceuticals where no brand is listed - listing of the hospital tender winning brand of the pharmaceuticals will occur in Part II of Section H of the Pharmaceutical Schedule on 1 August 2010 and DV Limits will apply from 1 October 2010.

The decisions were as follows:

Chemical Name Ascorbic acid Azathioprine Azathioprine Tamsulosin hydrochloride

Presentation; Pack size and type Tab 100 mg; 500 tablets, bottle Inj 50 mg; 1 injection, vial Tab 50 mg; 100 tablets, blister Cap 400 mg; 30 capsules, blister

Hospital Supply Brand (Supplier) Vitala-C (Boucher and Muir) Imuran (Aspen) Imuprine (Mylan) Tamsulosin-Rex (Rex Medical)

Pack Price $13.80 $60.00 $18.45 $5.98

DV Limit 1% 1% 1% 1%

Products where no tender is to be awarded for Sole Subsidised Supply or Hospital Supply Status The PHARMAC Board (or Chief Executive under delegated authority) resolved not to award tenders for Sole Subsidised Supply or Hospital Supply Status for some of the products listed in the Invitation to Tender dated 4 December 2009.

The decisions were as follows:

Chemical Name Doxazosin Mesylate Doxazosin Mesylate Ephedrine Ephedrine Methadone Hydrochloride Naproxen Naproxen Naproxen Sodium Naproxen Sodium Pethidine Hydrochloride Pethidine Hydrochloride Sodium Chloride Sodium Chloride Sodium Chloride

Line Item Tab 2 mg Tab 4 mg Inj 30 mg per ml, 1 ml Inj 30 mg per ml, 10 ml prefilled syringe Inj 10 mg per ml, 1 ml Tab long-acting 750 mg Tab long-acting 1,000 mg Tab 275 mg Tab 550 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml Inj 0.9%, 5 ml Inj 0.9%, 10 ml Inj 0.9%, 20 ml

Please note that all products included in the Invitation to Tender dated 21 December 2007 have now been resolved. For the remaining products in the Invitation to Tender dated 23 December 2008 and the Invitation to Tender dated 4 December 2009 where no announcement has been made, either a decision is still pending, or is provisional and subject to the product gaining market approval and having sufficient stock. We will keep you informed regarding any changes for the remaining tender products as further decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A351384 - qA15909

Page 4 of 4